Advanced glycation end products and the absence of premature atherosclerosis in glycogen storage disease Ia

Journal of Inherited Metabolic Disease

Volumn 30, Issue 6, 2007, Pages 916-923

  Hollander, N C ^a   Mulder, D J ^a   Graaff, R ^a   Thorpe, S R ^b   Baynes, J W ^b   Smit, G P A ^a   Smit, A J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; LYSINE; N CARBOXYETHYLLYSINE; PENTOSIDINE; UNCLASSIFIED DRUG; XANTHINE OXIDASE INHIBITOR;

ADULT; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; AUTOFLUORESCENCE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCOGEN STORAGE DISEASE TYPE 1; GLYCOGEN STORAGE DISEASE TYPE 1A; HUMAN; HUMAN TISSUE; INTERNAL CAROTID ARTERY; MALE; OXIDATIVE STRESS; SKIN BIOPSY;

ADOLESCENT; ADULT; ARGININE; ATHEROSCLEROSIS; CAROTID ARTERIES; COLLAGEN; FEMALE; GLYCOGEN STORAGE DISEASE TYPE I; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LYSINE; MALE; OXIDATIVE STRESS; RISK; SKIN; TUNICA INTIMA; TUNICA MEDIA;

EID: 37249070865     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-007-0507-0     Document Type: Article

References (41)

1. ε -(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J 324 (Pt 2): 565-570.
2. Baker L, Dahlem S, Goldfarb S, et al (1989) Hyperfiltration and renal disease in glycogen storage disease, type I. Kidney Int 35: 1345-1350.
3. Berry GT, Baynes JW, Wells-Knecht KJ, et al (2005) Elements of diabetic nephropathy in a patient with GLUT 2 deficiency. Mol Genet Metab 86: 473-477.
4. Butler R, Morris AD, Belch JJ, et al (2000) Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 35: 746-751.
5. Cardillo C, Kilcoyne CM, Cannon RO III, et al (1997) Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 30: 57-63.
6. Chen YT, Coleman RA, Scheinman JI, et al (1988) Renal disease in type I glycogen storage disease. N Engl J Med 318: 7-11.
7. Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creatsas G (2005) Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 62: 37-43.
8. Dyer DG, Dunn JA, Thorpe SR, et al (1993) Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91: 2463-2469.
9. Elgawish A, Glomb M, Friedlander M, Monnier VM (1996) Involvement of hydrogen peroxide in collagen cross-linking by high glucose in vitro and in vivo. J Biol Chem 271: 12964-12971.
10. Forbes JM, Yee LT, Thallas V, et al (2004) Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53: 1813-1823.
11. Fu MX, Wells-Knecht KJ, Blackledge JA, et al (1994) Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 43: 676-683.
12. Hershkovitz E, Rachmel A, Ben Zaken H, Phillip M (2001) Continuous glucose monitoring in children with glycogen storage disease type I. J Inherit Metab Dis 24: 863-869.
13. Kiuchi K, Nejima J, Takano T, et al (2001) Increased serum concentrations of advanced glycation end products: A marker of coronary artery disease activity in type 2 diabetic patients. Heart 85: 87-91.
14. Lee PJ (1994) Hyperlipidaemia does not impair vascular endothelial function in glycogen storage disease type 1a. Atherosclerosis 110: 95-100.
15. Levy E, Thibault LA, Roy CC, et al (1988) Circulating lipids and lipoproteins in glycogen storage disease type I with nocturnal intragastric feeding. J Lipid Res 29: 215-226.
16. Meerwaldt R, Oomen PHN, Links TP, et al (2004) Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 47: 1324-1330.
17. Meerwaldt R, Hartog JW, Graaff R, et al (2005a) Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 16: 3687-3693.
18. Meerwaldt R, Links T, Graaff R, et al (2005b) Simple noninvasive measurement of skin autofluorescence. Ann NY Acad Sci 1043: 290-298.
19. Meerwaldt R, Lutgers HL, Links TP, et al (2007) Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 30: 107-112.
20. Miyata T, Fu MX, Kurokawa K, et al (1998) Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: Is there oxidative stress in uremia? Kidney Int 54: 1290-1295.
21. Monnier VM, Vishwanath V, Frank KE, et al (1986) Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 314: 403-408.
22. Mulder DJ, Water TV, Lutgers HL, et al (2006) Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: An overview of current clinical studies, evidence, and limitations. Diabetes Technol Ther 8: 523-535.
23. Mundy HR, Lee PJ (2002) Glycogenosis type I and diabetes mellitus: A common mechanism for renal dysfunction? Med Hypotheses 59: 110-114.
24. Nakamura Y, Horii Y, Nishino T, et al (1993) Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 143: 1649-1656.
25. Nieto FJ, Iribarren C, Gross MD, et al (2000) Uric acid and serum antioxidant capacity: A reaction to atherosclerosis? Atherosclerosis 148: 131-139.
26. Rake JP, Visser G, Labrune P, et al (2002) Glycogen storage disease type I: Diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 161 (Supplement 1): S20-S34.
27. Ritthaler U, Deng Y, Zhang Y, et al (1995) Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol 146: 688-694.
28. ε-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 99: 457-468.
29. Selzer RH, Hodis HN, Kwong-Fu H, et al (1994) Evaluation of computerized edge tracking for quantifying intima-media thickness of the common carotid artery from B-mode ultrasound images. Atherosclerosis 111: 1-11.
30. Stegemann H, Stalder K (1967) Determination of hydroxyproline. Clin Chim Acta 18: 267-273.
31. Talente GM, Coleman RA, Alter C, et al (1994) Glycogen storage disease in adults. Ann Intern Med 120: 218-226.
32. Terpstra WF, May JF, Smit AJ, et al (2004) Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J Hypertens 22: 1309-1316.
33. Thorpe SR, Baynes JW (2003) Maillard reaction products in tissue proteins: New products and new perspectives. Amino Acids 25: 275-281.
34. Ubels FL, Rake JP, Slaets JP, et al (2002) Is glycogen storage disease 1a associated with atherosclerosis? Eur J Pediatr 161 (Supplement 1): S62-S64.
35. Verhave JC, Hillege HL, Burgerhof JG, et al (2005) The association between atherosclerotic risk factors and renal function in the general population. Kidney Int 67: 1967-1973.
36. Wells-Knecht KJ, Zyzak DV, Litchfield JE, et al (1995) Mechanism of autoxidative glycosylation: Identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 34: 3702-3709.
37. Wells-Knecht MC, Lyons TJ, McCance DR, et al (1997) Age-dependent increase in ortho-tyrosine and methionine sulfoxide in human skin collagen is not accelerated in diabetes. Evidence against a generalized increase in oxidative stress in diabetes. J Clin Invest 100: 839-846.
38. Wiegman A, De Groot E, Hutten BA, et al (2004) Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 363: 369-370.
39. Wittenstein B, Klein M, Finckh B, et al (2002) Plasma antioxidants in pediatric patients with glycogen storage disease, diabetes mellitus, and hypercholesterolemia. Free Radic Biol Med 33: 103-110.
40. Wolff SP, Dean RT (1987) Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J 245: 243-250.
41. Yudkin JS, Forrest RD, Jackson CA (1988) Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 2: 530-533.